Key result
Systemic administration of the TLR ligand CpG restored experimental autoimmune myocarditis in PKC-theta-deficient mice, which otherwise did not develop the disease.
TLR-mediated activation of T cells can directly overcome the requirement for PKC-theta signaling to promote the development of autoimmune myocarditis.
TLR activation may bypass PKC-theta in myocarditis models; hypothesis-generating for human autoimmune mechanisms.
The serine/threonine kinase, protein kinase C-theta (PKC-theta), plays a central role in the activation and differentiation of Th2 cells while being redundant in CD4+ and CD8+ antiviral responses. Recent evidence indicates that PKC-theta may however be required for some T cell-driven autoimmune responses. We have investigated the role of PKC-theta in the induction of autoimmune myocarditis induced by either Coxsackie B3 virus infection or immunization with alpha-myosin/CFA (experimental autoimmune myocarditis (EAM)). PKC-theta-deficient mice did not develop EAM as shown by impaired inflammatory cell infiltration into the heart, reduced CD4+ T cell IL-17 production, and the absence of a myosin-specific Ab response. Comparatively, PKC-theta was not essential for both early and late-phase Coxsackie virus-induced myocarditis. We sought to find alternate pathways of immune stimulation that might reconcile the differential requirements for PKC-theta in these two disease models. We found systemic administration of the TLR ligand CpG restored EAM in PKC-theta-deficient mice. CpG could act directly upon TLR9-expressing T cells to restore proliferation and up-regulation of Bcl-x(L), but exogenous IL-6 and TGF-beta was required for Th17 cell differentiation. Taken together, these results indicate that TLR-mediated activation of T cells can directly overcome the requirement for PKC-theta signaling and, combined with the dendritic cell-derived cytokine milieu, can promote the development of autoimmunity.
No takes yet. Share an insight, caveat, or question.
Marsland et al. (2007) studied Autoimmune myocarditis. TLR ligand CpG vs. No CpG / PKC-theta deficiency alone was evaluated on Development of experimental autoimmune myocarditis. Systemic administration of the TLR ligand CpG restored experimental autoimmune myocarditis in PKC-theta-deficient mice, which otherwise did not develop the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: